Finance
Roche to complete $1.5 billion acquisition of U.S. biopharma company Poseida
Published by Global Banking and Finance Review
Posted on January 24, 2025
2 min readLast updated: January 27, 2026
Global Banking and Finance Review
Company
Published by Global Banking and Finance Review
Posted on January 24, 2025
2 min readLast updated: January 27, 2026
Roche completes its $1.5 billion acquisition of Poseida Therapeutics, enhancing its biopharma pipeline with advanced CAR-T cell therapies.
ZURICH (Reuters) -Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics , a specialist in complex immune cell therapies to treat several types of blood cancer.
Roche said it has accepted for payment nearly 65 million shares in Poseida - equivalent to 66% of the California company's stock - which had been tendered by shareholders at a price of $9 per share, with an additional contingent payment of up to $4 per share.
The consideration takes the deal value up to around $1.5 billion.
The acquisition, announced in November, is the latest move by Roche to boost its development pipe-line to offset falling oncology sales.
"Later today, Roche intends to complete the acquisition of Poseida ...without a vote or meeting of Poseida's stockholders," Roche said on Wednesday.
In the takeover, all shares of Poseida not owned by Poseida, or Roche will be converted into the right to receive the same consideration per share, the Swiss company said.
Poseida, which will become a wholly owned subsidiary of Roche, will add so-called allogeneic CAR-T cell therapies, which use genetically modified immune cells to attack cancer cells or to treat auto immune diseases.
Poseida is also working on CAR-T programmes for solid tumours and autoimmune diseases.
(Reporting by John Revill, editing by Rachel More)
The article discusses Roche's $1.5 billion acquisition of Poseida Therapeutics, a biopharma company specializing in CAR-T cell therapies.
Poseida specializes in complex immune cell therapies, including CAR-T cell therapies for blood cancer and autoimmune diseases.
Roche aims to enhance its development pipeline and offset declining oncology sales by acquiring Poseida's innovative therapies.
Explore more articles in the Finance category
